Moderna, Inc. (MRNA:NASDAQ) closed at $202.63 on October 22, 2026, down 17.57% on the day. The stock trades 20.4% below its 52-week high of $254.48 and 809.5% above its 52-week low of $22.28. Over the past year, it gained 815.5%. Moderna, Inc. is part of the Health Care sector.
In 252 trading sessions since October 22, 2025, MRNA closed higher on 133 days (53%). Its best day was August 19, 2026 (+176.97%) and its worst was August 20, 2026 (-23.55%). The stock moved 10% or more in a single session 16 times. It opened at least 5% above the previous day's high 2 times.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 24 mRNA development programs as of early 2021, with 13 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Find more stocks like MRNA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.